Nigeria Pharmaceuticals Market: By Product Type, By Formulation, By Therapeutic Area, By Distribution Channel and Country Forecast 2020-2031
Nigeria Pharmaceuticals Market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031. Pharmaceuticals are the drugs used to diagnose, treat, prevent, or cure the various diseases. The increase in the prevalence of infectious diseases such as Malaria (approximately 300,000 deaths occur due to malaria) and diarrhea (according to WHO, approximately 10% deaths occur due to diarrheal disease), expansion of businesses by global market players by acquiring local companies are anticipated to fuel the Nigeria pharmaceuticals market. Moreover, rise in incidence of chronic diseases such as AIDS and cancer, rapid urbanization, and rise in healthcare expenditure are expected to boost the Nigeria pharmaceuticals market over the forecast years. However, lack of R&D activities may hinder the growth of Nigeria pharmaceuticals market over forecast period.
|
Report Benchmarks |
Details |
|
By Product Type |
|
|
By Formulation |
|
|
By Therapeutic Area |
|
|
By Distribution Channel |
|
Download Free Sample Report
Nigeria pharmaceuticals market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X%.
The market Key Players are Biogaran S.A.S, Fidson Healthcare PLC, GlaxoSmithKline PLC, Emzor Pharmaceutical Industries Ltd.
2024 is the base year and 2025-2031 is the forecast period of the market.
| 1.Executive Summary |
| 2. Nigeria Pharmaceuticals Market Introduction |
| 2.1. Nigeria Pharmaceuticals Market - Taxonomy |
| 2.2. Nigeria Pharmaceuticals Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Formulation |
| 2.2.3.Therapeutic Area |
| 2.2.4.Distribution Channel |
| 3. Nigeria Pharmaceuticals Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Nigeria Pharmaceuticals Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Nigeria Pharmaceuticals Market By Product Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Prescription Drugs |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Over-the-Counter Drugs |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Nigeria Pharmaceuticals Market By Formulation, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Solid |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Liquid |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Semi-Solid |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Nigeria Pharmaceuticals Market By Therapeutic Area, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Infectious Diseases |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Malaria |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Diarrhea |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. AIDS |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Hepatitis |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Tuberculosis |
| 7.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Other Infectious Diseases |
| 7.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 7.8. Cardiovascular Diseases |
| 7.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.8.3. Market Opportunity Analysis |
| 7.9. Diabetes and Metabolic Disorders |
| 7.9.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.9.3. Market Opportunity Analysis |
| 8. Nigeria Pharmaceuticals Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9. Competition Landscape |
| 9.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 9.2.1.Biogaran S.A.S |
| 9.2.2.Servier laboratories |
| 9.2.3.Fidson Healthcare PLC |
| 9.2.4.GlaxoSmithKline PLC |
| 9.2.5.Emzor Pharmaceutical Industries Ltd. |
| 9.2.6.Emzor Chemists Limited |
| 9.2.7.May & Baker Nigeria Plc. |
| 9.2.8.Chemiron International Limited |
| 9.2.9.Zolon healthcare limited. |
| 9.2.10.NEROS Pharmaceuticals Ltd. |
| 10. Research Methodology |
| 11. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
